Although there is evidence to suggest that genetic factors play a major role in the pathogenesis of many of the rheumatic diseases, far less is known of their role in the induction and expression of human autoimmunity resulting from long-term exposure to drugs, chemicals and environmental agents.
Pharmacogenetic factors represent an important source of interindividual variation in response to drugs; most research to date has focused on genetic polymorphism of drug metabolism via N-acetylation, S-methylation or cytochrome P-450-catalyzed oxidation.
In drug-related autoimmunity, there is limited evidence that the host's genetic background plays a major role beyond the expression of autoantibodies.
More recent prospective studies have concentrated on the association of MHC-genes in the expression of autoimmunity and the susceptibility of patients to develop drug-related clinical syndromes.
Oliveira Dbg.Genetics and autoimmunity. J Royal Soc Med1992; 85: 653-5.
2.
Arnett FCGenetic aspects of human lupus. Clin Immunol Immunopath1992; 63: 4-6.
3.
Cowland JB, Andersen V., Halberg P., Morling N.DNA polymorphism of HLA class II genes in systemic lupus erythematosus. Tissue Antigens1994; 43: 34-7.
4.
Wilson AG, De Vries N., Pociot F. et al. An allelic polymorphism within the human tumor necrosis factor-alpha promoter region is strongly associated with HLA-A1, B8 and DR3 alleles. J Exp Med1993; 177: 577-60.
5.
Matsuyama S. , Koide Y., Yoshide TOHLA class II molecule-mediated signal transduction mechanism responsible for the expression of interleukin-1β and tumor necrosis factor-α genes induced by a staphylococcal superantigen. Eur J Immunol1993 ; 34: 3194-202.
6.
Bailly S., di Giovine, S., Blakemore Aif, Duff GWGenetic polymorphism of human interleukin-1αEur J Immunol1993 ; 23: 1240-5.
7.
Wordsworth BP , Pile KD, Gibson K., Burney RO, Mockridge I., Powis SHAnalysis of the MHC-encoded transporters TAP1 and TAP2 in rheumatoid arthritis: linkage with DR4 accounts for the association with a minor TAP2 allele. Tissue Antigens1993; 42: 153-5.
8.
Glimcher LH, Kara CJSequences and factors: a guide to MHC class II transcription. Ann Rev Immunol1992; 10: 13-49.
Guardiola J. , Maffei A.Control of MHC class II gene expression in autoimmune, infectious and neoplastic diseases. Crit Rev Immunol1993; 13: 247-68.
11.
Adams LE, Hess EVDrug-related lupus. Incidence, mechanisms and clinical implications. Drug Safety1991; 6: 431-49.
12.
Hess EV, Mongey A-B.Drug-related lupus: the same or different. In: Systemic Lacpacs Erythematosus, 2nd edn. Lahita RG (ed.). New York: Churchill-Livingstone , 1992: 893-904.
13.
Fritzer MJDrugs recently associated with lupus syndromes. Lupus1994; 3: 455-459.
14.
Bigazzi PEAutoimmunity and heavy metals. Lacpacs1994 ; 3: 449-453.
15.
Kausman D., Isenberg DAThe role of the biologics in autoimmunity. Lupus1994; 3: 461-466.
16.
Mongey A-B. , Donovan-Brand RJ, Thomas TJ, Adams LE, Hess EVSerologic evaluation of patients receiving procainamide. Arthritis Rheum1992; 35: 219-23.
17.
Adams LE, Balakrishnan K., Roberts SM et al. Genetic, immunologic and biotransformation studies of patients on procainamide. Lupus1993; 2: 89-98.
18.
Rubin RLRole of xenobiotic oxidation metabolism. Lupus1994; 3: 479-482.
19.
Nepom GT, Erlich H.MHC class II molecules and autoimmunity. Ann Rev Immunol1991; 9: 493-525.
20.
Howard PF, Hochberg MC, Bias WB, Arnett FC, McLean RHRelationship between C4 null genes, HLA-D region antigens and genetic susceptibility to systemic lupus erythematosus in Caucasians and black Americans. Am J Med1986; 81: 187-93.
21.
Schur PH, Marcus-Babley D., Awdeh Z., Yunis EJ, Alper CAThe effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus. Arthritis Rheum1990; 33: 985-92.
22.
Dong R-P., Kimura A., Hashimoto H., Akizuki M., Nichimura Y., Sasazuki T.Difference in HLA-lined genetic background between mixed connective tissue disease and systemic lupus erythematosus. Tissue Antigens1993; 41: 20-5.
23.
Arcavi L., Benowitz NLClinical significance of genetic influences on cardiovascular drug metabolism . Cardiovasc Drugs Therapy1993; 7: 311-24.
24.
Stephens Haf , Sakkas LI, Vaughan RW, Teitsson I., Welsh LI, Panayi GSHLA-Dqw7 is a disease severity marker in patients with rheumatoid arthritis. Immunogenetics1989; 30: 119-22.
25.
Maddison PJ , Isenberg DA, Goulding NJ, Leddy J., Skinner RPAnti-La (SSB) identifies a distinctive subgroup of systemic lupus erythematosus. Br J Rheumatol1988 ; 27: 27-31.
Batchelor JR , Welsh KI, Tinoco RM et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet1980; i: 1102-9.
28.
Brand C., Davison A., Littlejohn G., Ryan P.Hydralazine-induced lupus: no association with HLA-DR4. Lancet1984; 2: 462.
29.
Russell GI, Bing RF, Jones Jag, Thurston H., Swales JDHydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype. Q J Med1987; 65: 845-52.
30.
Speirs C., Fiedler Ahl, Chapel H., Davey NT, Batchelor JRComplement system protein C4A and susceptibility to hydralazine-induced systemic lupus erythematosus. Lancet1989; 1: 922-4.
31.
Whiteside T. , Mulhern L., Buckingham R., Luksock J.Procainamide induced lupus (PLE) is associated with an increase frequency of HLA-DR 6YArthritis Rheum1982; 25: S41 (abstract).
Canoso RP, Lewis ME, Yunis EJAssociation of HLA BW44 with chlorpromazine-induced autoantibodies. Clin Immunol Immunopath1982; 25: 278-82.
34.
Ayesh R., Mitchell SC, Waring RH et al. Sodium aurothiomalate toxicity and sulphoxidation capacity in rheumatoid arthritis patients. Br J Rhetimatol1987; 26: 197-201.
35.
Emery P., Panayi GS, Husten G.D-penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol1984 ; 11: 626-32.
36.
Chalmers A. , Thompson D., Stein HE et al. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. Ann Intern Med1982; 97: 659-63.
37.
Black CM, Maddison PJ, Welsh KI, Bernstein R., Woodrow JC, Pereira RSHLA and immunoglobulin allotypes in mixed connective tissue disease. Arthritis Rheum1988; 31: 131-4.
38.
Grosse-Wilde M., Genth E., Grevesmuhl A. et al. HLA-DR4 and GM 1;21 haplotypes are associated with pseudolupus induced by Venopyronum dragees. Arthritis Rheum1987; 30: 878-83.
39.
Richeldi L. , Sorrentino R., Saltini C.DPB I glutamate 69: a genetic marker of beryllium disease. Science1993; 262: 242-4.
40.
Oursler JR, Farmer ER, Roubenoff R. et al. Cutaneous manifestations of the easinaphilia-myalgia syndrome . Br J Dermatol1992; 127: 138-46.
41.
Kaufman L., Pampate J., Gruber B. et al. L-tryptophan eosinophilia myalgia syndrome (TEMS): clinical follow-up and immunogenetic studies of 25 patients. Arthritis Rheum1990; 33: S17 (abstract).
42.
Varga J., Heiman-Patterson TD, Emery DL et al. Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome. Semin Arthritis Rheum1990; 19: 313-28.
43.
Adams LE, Roberts SM, Donovan-Brand R., Zimmer H., Hess EVStudy of procainamide hapten-specific antibodies in rabbits and humans. Int J Immunopharmac1993; 15: 887-9.
44.
Pociot F., Molvig, J., Wogensen L. et al. A tumor necrosis factor-beta gene polymorphism in relation to monokine secretion and insulin-dependent diabetes mellitus, Scand J Immunol1991; 33: 37-49.
Reidenberg MM, Drayer DE, Levy M., Warner H.Polymorphic acetylation of procainamide in man. Clin Pharmacol Ther1975; 17: 722-30.
47.
Litwin A., Adams LE, Zimmer H., Foad B., Loggie JH, Hess EVProspective study of immunologic effects of hydralazine in hypertensive patients . Clin Pharmacol Ther1981; 24: 447-56.
48.
Roberts SM, Budinsky RA, Adams LE, Litwin A., Hess EVProcainamide acetylation in strains of rat and mouse. Drug Metabol Disposit1985; 13: 517-19.
49.
Hein DW, Weber WWMetabolism of procainamide, hydralazine and isoniazid in relation to autoimmune(-like) reactions. In: Autoimmunity and Toxicology. Kammuller ME, Bloksma N, Seinen W (eds). Amsterdam: Elsevier Science Publishers, 1989: 239.
50.
Gelber R., Perters JH, Gordon GRThe polymorphic acetylation of dapsone in man. Clin Pharmacol Ther1971; 12: 225-38.
51.
Kalow W.Ethnic differences in drug metabolism. Clin Pharmacokin1982; 7: 373-400.
52.
Lou YCDifferences in drug metabolism polymorphism between Orientals and Caucasians . Drug Metab Rev1990; 22: 451-75.
53.
Grant DM, Morike K., Eichelbaum M., Meyer UAAcetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver. J Clin Invest1990; 85: 968-72.
54.
Hutabarat RW , Smith AL, Unadkat JDDisposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells. In vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes. Clin Pharmacol Ther1994; 55: 427-33.
55.
Cribb AE, Grant DM, Miller MA, Speilberg SPExpression of monomorphic arylamine N-acetyltransferase (NAT-1) in human leukocytes . J Pharmacol Exp Ther1991; 259: 1241-6.
56.
Reidenberg MMThe chemical induction of systemic lupus erythematosus and lupus-like illnesses. Arthritis Rheum1981; 24: 1004-8.
57.
Roberts SM, Adams LE, Donovan-Brand R. et al. Procainamide hydraxylamine lymphocyte toxicity. I. Evidence for participation by hemoglobin. Int J Immunopharmac1989; 11: 419-27.
58.
Adams LE, Sanders CE Jr, Budinsky RA, Donovan-Brand R., Roberts SM, Hess EVImmunomodulatory effects of procainamide metabolites: their implications in drug-related lupus. J Lab Clin Med1989; 113: 482-92.
59.
Guengerich FP, Distlerath LM, Reilly Peb.Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. Xenobiotica1986; 16: 367-78.
60.
Nebert DW, Weber WWPharmacogenetics. In: Principles of Drug Action. The Basis of Pharmacology, 3rd edn. Pratt WB, Taylor PW (eds). New York: Churchill Livingstone1990: 469.
61.
McKinnon RA , Nebert DWPossible role of cytochromes P450 in lupus erythematosus and related disorders. Lupus1994; 3473-478.
62.
Adams LE, Roberts SM, Carter JM et al. Effects of procainamide hydroxylamine on generation of reactive oxygen species by macrophages and production of cytokines. Int J Immunopharm1990; 12: 809-19.
63.
Wheeler JF, Adams LE, Mongey A-B., Roberts SM, Heineman WR, Hess EVDetermination of metabolically-derived nitroprocainamide in the urine of procainamide-dosed humans and rats by liquid chromatography with electrochemical detection. Drug Metabol Disposit1991; 19: 691-5.
64.
Thomas TJ, Seibold JR, Adams LE, Hess EVHydralazine induces Z-DNA conformation in a polynucleotide and elicits anti(Z-DNA) antibodies in treated patients. Biochem J1993; 294: 419-25.
65.
Baer AN, McAllister CB, Wilkinston GR et al. Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum1986; 29: 843-50.
